<DOC>
	<DOCNO>NCT01942265</DOCNO>
	<brief_summary>This Phase II randomize , double-blinded , control study 1000 males non-pregnant female , 19 64 year old , inclusive , good health meet eligibility criterion design provide data A/H7N9 vaccine make HA antigen derive influenza A/Shanghai/2/2013 virus .</brief_summary>
	<brief_title>H7N9 Mix Match With AS03 MF59 Healthy Adults</brief_title>
	<detailed_description>This Phase II randomize , double-blinded , control study 1000 males non-pregnant female , 19 64 year old , inclusive , good health meet eligibility criterion design provide data A/H7N9 vaccine make HA antigen derive influenza A/Shanghai/2/2013 virus . The study aim address several critical question , include safety , reactogenicity , immunogenicity monovalent influenza A/H7N9 virus vaccine manufacture Sanofi Pasteur : 1 ) two dos administer different dosage ( 3.75 , 7.5 , 15 mcg HA/0.5 mL dose ) give AS03 adjuvant manufacture GlaxoSmithKline Biologicals without adjuvant ( 15 mcg HA/0.5 mL dose 45 mcg HA/0.75 mL dose ) ; 2 ) combination two dos A/H7N9 vaccine ( 15 mcg HA/0.5 mL dose ) administer different adjuvant ( AS03 MF59 manufacture Novartis Vaccines Diagnostics ) ; 3 ) two dos administer 15 mcg HA/0.5 mL dose give MF59 adjuvant manufacture Novartis Vaccines Diagnostics .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Provide write informed consent prior initiation study procedure . Are able understand comply plan study procedure available study visit . Are male nonpregnant female , 19 64 year old , inclusive . Are good health , determine vital sign ( oral temperature , pulse , blood pressure ) , medical history , target physical examination base medical history ensure exist medical diagnosis condition ( except Subject Exclusion Criteria ) stable . Subjects may chronic1 need ( prn ) medication , opinion site principal investigator appropriate subinvestigator , pose additional risk subject safety assessment reactogenicity immunogenicity . Note : Topical , nasal , inhaled medication ( exception steroid outline Subjects Exclusion Criteria ( see Section 5.2 ) , vitamin , contraceptive permit . Oral temperature le 100.4 degree F. Pulse 50 115 bpm , inclusive . Systolic blood pressure 85 150 mm Hg , inclusive . Diastolic blood pressure 55 95 mmHg , inclusive . Erythrocyte sedimentation rate ( ESR ) less 30 mm per hour . Alanine aminotransferase ( ALT ) less 44 IU/L female less 61 IU/L male . Creatinine le 1.11 mg/dL female less 1.38 mg/dL male . White blood cell ( WBC ) great 3.9 x10^3/UL less 10.6 x10^3/UL . Hemoglobin great 11.4 g/dL female great 12.4 g/dL male . Platelets great 139 x10^3/UL less 416 x10^3/UL . Total bilirubin le 1.3 mg/dL . Female subject childbearing potential surgically sterile via tubal sterilization , bilateral oophorectomy , hysterectomy postmenopausal &gt; /= 1 year must agree practice highly effective contraception may include , limited , abstinence intercourse male partner , monogamous relationship vasectomize partner , male condom use applied spermicide , intrauterine device , license hormonal method use highly effective method contraception minimum 30 day prior study product exposure agree practice highly effective contraception duration study product exposure , include 2 month ( define 60 day ) last study vaccination . A highly effective method contraception define one result low failure rate ( i.e. , less 1 percent per year ) use consistently correctly . Method contraception capture appropriate data collection form . Female subject childbearing potential must negative urine serum pregnancy test within 24 hour prior study vaccination . Have acute illness within 72 hour prior study vaccination . Have condition , opinion site principal investigator appropriate subinvestigator , would place subject unacceptable risk injury , render subject unable meet requirement protocol , confound interpretation result . Have acute chronic medical condition , opinion site principal investigator appropriate subinvestigator , would render vaccination unsafe , would interfere evaluation response . Have immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy ( cytotoxic ) within 3 year prior study vaccination . Have know active neoplastic disease history hematologic malignancy . Have know HIV , hepatitis B , hepatitis C infection . Have know hypersensitivity allergy egg , egg chicken protein , squalenebased adjuvant , component study vaccine . Have history severe reaction follow previous immunization license unlicensed influenza virus vaccine . Have personal family history narcolepsy without cataplexy . Have history GuillainBarr√© Syndrome . Have history neuralgia , paresthesia , neuritis , convulsion , encephalomyelitis within 90 day prior study vaccination . Have history autoimmune disease , include limited neuroinflammatory disease , vasculitis , clot disorder , dermatitis , arthritis , thyroiditis , muscle , liver kidney disease . Have history alcohol drug abuse within 5 year prior study vaccination . Have diagnosis , current past , schizophrenia , bipolar disease , psychiatric diagnosis may interfere subject compliance safety evaluation . Have hospitalize psychiatric illness , history suicide attempt , confinement danger self others within 10 year prior study vaccination . Have take oral parenteral corticosteroid dose within 30 day prior study vaccination . Have take highdose inhaled corticosteroid within 30 day prior study vaccination . Highdose define &gt; 800mcg/day beclomethasone dipropionate CFC equivalent . Received licensed live vaccine within 30 day license inactivated vaccine within 14 day prior first study vaccination plan receipt vaccine first study vaccination followup visit approximately 21 day last study vaccination . This inclusive license seasonal influenza vaccine . Received immunoglobulin blood product ( exception Rho D immunoglobulin ) within 90 day prior study vaccination . Received experimental agent ( vaccine , drug , biologic , device , blood product , medication ) within 30 day prior first study vaccination , expect receive experimental agent participation study 13month study period . Are participate plan participate another clinical trial interventional agent ( license unlicensed vaccine , drug , biologic , device , blood product , medication ) 13month study period . Prior participation clinical trial influenza A/H7 vaccine assign group receive influenza A/H7 vaccine ( apply document placebo recipient ) history A/H7 actual potential exposure infection prior first study vaccination . Plan travel outside U.S. ( continental U.S. , Hawaii Alaska ) time first study vaccination 42 day first study vaccination . Female subject breastfeed plan breastfeed give time first study vaccination 30 day last study vaccination . Blood donation within 30 day prior enrollment within 30 day last blood draw ( subset healthy adult subject volunteer , 1964 year old , enrol Vanderbilt VTEU site , consent blood donation immunology exploratory assay ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Influenza , Immunogenicity , Monovalent , A/H7N9 , Vaccine , AS03 , Adjuvant</keyword>
</DOC>